LAS VEGAS, Dec. 16, 2025 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), an emerging biotechnology company focused on developing cell-based therapies for diabetes ...
Avant Technologies, Art-Islets, and Austrianova Announce Joint Venture to Advance Diabetes Treatment
LAS VEGAS, Sept. 24, 2025 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), a Nevada-based corporation, Art-Islets Pte. Ltd. ("Art ...
In a landmark first-in-human study, researchers have harnessed a patient's own fat-derived stem cells—chemically reprogrammed into insulin-producing islets—to restore blood sugar control without daily ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback